Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

MTNB

Matinas Biopharma Holdings Inc

0.6424

Jun 26 • 04:00PM ET +0.0196 (3.15%)

Healthcare Biotechnology USA Nano AMEX

Jun 26, 5:50 PMMatinas BioPharma gets NYSE American equity non-compliance notice but keeps listing with compliance deadline of October 2, 2027

Peers: APRE BCDA BIVI CALC CVM GOVX KAPA KPRX LNAI NEUP

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.02	Insider Own	18.82%	Shs Outstand	6.41M	Perf Week	6.36%
Market Cap	4.12M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	5.20M	Perf Month	-12.06%
Enterprise Value	2.86M	PEG	-	EPS next Q	-	Inst Own	5.68%	Short Float	0.39%	Perf Quarter	7.71%
Income	-11.23M	P/S	-	EPS this Y	-	Inst Trans	-4.53%	Short Ratio	0.13	Perf Half Y	-4.13%
Sales	0.00M	P/B	1.36	EPS next Y	-	ROA	-125.39%	Short Interest	0.02M	Perf YTD	9.62%
Book/sh	0.47	P/C	1.68	EPS next 5Y	-	ROE	-241.67%	52W High	3.09 -79.21%	Perf Year	-31.80%
Cash/sh	0.38	P/FCF	-	EPS past 3/5Y	25.49% 19.44%	ROIC	-321.63%	52W Low	0.48 33.83%	Perf 3Y	-96.43%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.52% 11.25%	Perf 5Y	-98.37%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	49.11%	Oper. Margin	-	ATR (14)	0.07	Perf 10Y	-98.04%
Dividend Ex-Date	-	Quick Ratio	1.32	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.91	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.32	EPS Q/Q	7.86%	SMA20	-13.19%	Beta	1.73	Target Price	30.00
Payout	-	Debt/Eq	0.39	Sales Q/Q	-	SMA50	-3.99%	Rel Volume	0.24	Prev Close	0.62
Employees	4	LT Debt/Eq	0.16	Earnings	-	SMA200	-28.45%	Avg Volume	151.14K	Price	0.64
IPO	Jul 21, 2014	Option/Short	No / Yes	EPS/Sales Surpr.	19.43% -	Trades		Volume	35,719	Change	3.15%

Date	Action	Analyst	Rating Change	Price Target Change
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral
Aug-26-20	Resumed	Piper Sandler	Overweight
Jan-27-20	Initiated	Piper Sandler	Overweight	$3
Jan-24-20	Initiated	SunTrust	Buy
Jan-23-20	Initiated	SunTrust	Buy
Jan-09-20	Initiated	Aegis Capital	Buy	$3.50
Jun-26-19	Initiated	H.C. Wainwright	Buy	$4

Jun-26-26 05:15PM	Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance (GlobeNewswire)
Apr-03-26 05:00PM	Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards (GlobeNewswire)
Sep-23-25 07:22PM	Matinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203 (Insider Monkey) -5.83%
Mar-11-25 07:00AM	Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Feb-13-25 05:00PM	Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors (GlobeNewswire)
07:30AM	Loading…
Feb-07-25 07:30AM	Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair (GlobeNewswire) +8.79%
Jan-10-25 05:15PM	Matinas BioPharma Receives NYSE Noncompliance Notice (GlobeNewswire) -6.63%
Oct-31-24 06:30AM	Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction (GlobeNewswire) -67.88%
Oct-25-24 01:01PM	Highbridge Capital Management's Strategic Acquisition in Matinas BioPharma (GuruFocus.com)
Sep-02-24 09:21AM	Upcoming Stock Splits This Week (September 2 to September 6) Stay Invested (TipRanks)
Aug-14-24 04:05PM	Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-07-24 07:00AM	Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024 (GlobeNewswire)
Jun-24-24 08:30AM	Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program (GlobeNewswire) +6.69%
Jun-13-24 07:00AM	Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin (GlobeNewswire)
May-16-24 07:00AM	New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024 (GlobeNewswire)
01:22PM	Loading…
May-10-24 01:22PM	Q1 2024 Matinas BioPharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
12:46PM	Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 04:05PM	Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
May-07-24 08:00AM	Matinas BioPharma's LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting (GlobeNewswire)
May-02-24 07:00AM	Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024 (GlobeNewswire)
Apr-30-24 08:00AM	In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy (GlobeNewswire)
Apr-03-24 08:30AM	Matinas BioPharma Prices $10 Million Registered Direct Offering (GlobeNewswire) -35.00%
Apr-01-24 02:24PM	Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript (Insider Monkey) +36.46%
Mar-28-24 06:46AM	Q4 2023 Matinas BioPharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -6.52%
Mar-27-24 04:05PM	Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Mar-25-24 08:00AM	Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation (GlobeNewswire)
Mar-22-24 12:37PM	Why Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday? (Benzinga)
09:15AM	Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response (GlobeNewswire)
06:30AM	Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards (GlobeNewswire)
Feb-26-24 08:00AM	Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution (GlobeNewswire) +12.36%
07:30AM	Loading…
Feb-20-24 07:30AM	Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis (GlobeNewswire)
Jan-03-24 07:00AM	Matinas BioPharma to Present at Biotech Showcase 2024 (GlobeNewswire)
Dec-27-23 07:30AM	Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides (GlobeNewswire) +20.42%
Dec-21-23 07:30AM	Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA (GlobeNewswire)
Nov-10-23 01:15PM	Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q3 2023 Earnings Call Transcript (Insider Monkey) -12.01%
Nov-09-23 08:52AM	12 Best Day Trading Stocks To Buy (Insider Monkey) -12.18%
08:41AM	Q3 2023 Matinas BioPharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 06:42PM	Matinas BioPharma Holdings Inc (MTNB) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -13.78%
04:05PM	Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-07-23 07:30AM	Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model (GlobeNewswire) +27.19%
Nov-01-23 07:00AM	Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023 (GlobeNewswire)
Oct-11-23 07:30AM	Patient with Candida krusei Infection in Matinas BioPharmas Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution (GlobeNewswire) +313.55%
Sep-28-23 07:00AM	Matinas BioPharma to Present at Two Investment Conferences in October 2023 (GlobeNewswire)
Sep-27-23 07:00AM	Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek (GlobeNewswire) -6.60%
Sep-22-23 05:25PM	Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency (GlobeNewswire) -6.72%
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-06-23 07:00AM	Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire) -5.33%
Aug-22-23 07:30AM	Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases (GlobeNewswire)
Aug-10-23 11:05AM	Q2 2023 Matinas BioPharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -40.91%
Aug-09-23 04:05PM	Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-02-23 07:00AM	Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jul-26-23 08:00AM	Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023 (GlobeNewswire)
May-11-23 01:44PM	Why Matinas BioPharma Stock Is Sinking Today (Benzinga) -29.72%
07:30AM	Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023 (GlobeNewswire)
06:30AM	Q1 2023 Matinas BioPharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
May-10-23 05:15PM	Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.06%
04:05PM	Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
May-03-23 07:00AM	Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023 (GlobeNewswire)
May-02-23 02:16PM	Matinas BioPharma shares lipid nanocrystal platform delivery for emerging anti-fungal drug (News Direct)
Apr-27-23 06:36PM	7 Small-Cap Biotech Stocks with Massive Potential (InvestorPlace)
Apr-18-23 08:00AM	Compassionate Use Patient Treated with Matinas BioPharmas MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID (GlobeNewswire) +13.63%
Mar-18-23 03:12AM	Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-16-23 05:42AM	Q4 2022 Matinas BioPharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents) +6.86%
Mar-15-23 04:05PM	Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update (GlobeNewswire)
Mar-08-23 07:00AM	Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023 (GlobeNewswire)
Mar-02-23 07:00AM	Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID (GlobeNewswire)
Jan-30-23 04:01PM	Matinas BioPharma Provides Business Update and 2023 Strategic Outlook (GlobeNewswire)
Jan-23-23 07:00AM	Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023 (GlobeNewswire)
Jan-20-23 10:49AM	12 Hot Penny Stocks On the Rise (Insider Monkey)
Jan-12-23 07:00AM	Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids (GlobeNewswire)
Nov-02-22 05:55PM	Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:02PM	Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress (GlobeNewswire)
Oct-27-22 07:00AM	Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2022 Operational and Financial Results on November 2, 2022 (GlobeNewswire)
Oct-24-22 05:30AM	Deadly Fungi Are Infecting More Americans (The Wall Street Journal) -5.93%
Oct-21-22 07:48AM	Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90% (GlobeNewswire) +22.15%
07:00AM	Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference (GlobeNewswire)
Oct-19-22 07:10AM	Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022 (GlobeNewswire)
Oct-12-22 07:00AM	Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022 (GlobeNewswire)
Sep-21-22 07:00AM	Matinas BioPharma Announces Chairman Succession Plan (GlobeNewswire) +6.17%
Sep-07-22 07:00AM	Matinas BioPharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-30-22 09:35AM	After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Matinas Biopharma Holdings, Inc. (MTNB) (Zacks)
Aug-11-22 07:45AM	Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress (GlobeNewswire)
Aug-01-22 07:00AM	Matinas BioPharma to Participate in the BTIG Biotechnology Conference (GlobeNewswire)
Jul-28-22 04:15PM	Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022 (GlobeNewswire)
Jul-25-22 06:30AM	Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 for the Treatment of Cryptococcosis (GlobeNewswire) +5.83%
Jun-20-22 09:22AM	10 Best Biotech Penny Stocks To Buy Now (Insider Monkey)
May-31-22 07:00AM	Matinas BioPharma to Present at the LD Micro Invitational XII Conference (GlobeNewswire)
May-12-22 07:45AM	Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights (GlobeNewswire)
May-05-22 07:00AM	Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2022 Financial and Operational Results on May 12, 2022 (GlobeNewswire)
May-03-22 07:00AM	Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference (GlobeNewswire)
Apr-12-22 02:51PM	Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines (Zacks) -10.04%
Apr-11-22 11:52AM	Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech (Benzinga) +23.25%
07:00AM	BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines (GlobeNewswire)
Apr-06-22 07:00AM	Matinas BioPharma to Present at the Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-22-22 07:00AM	Matinas BioPharma to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire) +5.56%
Mar-16-22 10:00AM	Matinas Biopharma Holdings, Inc. (MTNB) Loses 29.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +11.27%
Mar-08-22 06:30AM	Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights (GlobeNewswire) +5.44%
Feb-28-22 07:00AM	Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial and Operational Results on March 8, 2022 (GlobeNewswire) -5.06%

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Co-FounderMr. Jerome D. Jabbour J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MTNB

Matinas Biopharma Holdings Inc

Upgrade your Finviz experience